Volume 4, Issue 4, August 2016, Page: 20-26
IL-18 and Anti- P. gingivalis Antibodies in Patients with Diabetes and Chronic Periodontitis
Romero-Herrera Coralia, Faculty of Odontology, Autonomous University of Nuevo León, Monterrey, Nuevo León, México
De La Rosa-Ramírez Antonio Manuel, Periodontics, University of Monterrey (UDEM), Monterrey, Nuevo León, México
Rosas-Taraco Adrián Geovanni, Immunology Department, Faculty of Medicine, Autonomous University of Nuevo León, Monterrey, Nuevo León, México
Limón-Flores Alberto Yairh, Immunology Department, Faculty of Medicine, Autonomous University of Nuevo León, Monterrey, Nuevo León, México
Arce-Mendoza Alma Yolanda, Immunology Department, Faculty of Medicine, Autonomous University of Nuevo León, Monterrey, Nuevo León, México
Received: Sep. 15, 2016;       Accepted: Oct. 12, 2016;       Published: Nov. 1, 2016
DOI: 10.11648/j.iji.20160404.11      View  2840      Downloads  96
Abstract
Periodontitis is an important complication in patients with diabetes mellitus. Chronic periodontitis is caused mostly by Porphyromonas gingivalis in Mexico, and by proinflammatory cytokines like IL-1, IL-6, TNFa, and IL-18. The aim of our study was to quantify IL-18 and to detect antibodies against P. gingivalis in gingival crevicular fluid of type 2 diabetes mellitus (T2DM) patients with chronic periodontal disease (PD). We studied a total of 40 patients divided in four groups: group 1 T2DM patients with PD, group 2 T2DM patients without PD, group 3 non-diabetic patients with PD, and a control group of healthy individuals. IL-18 was quantified using a commercial ELISA kit. Detection of IgG and IgM antibodies in gingival crevicular fluid was carried out through ELISA using P. gingivalis semi-purified proteins. Our results showed T2DM patients with chronic PD had low levels of IL-18, whereas non-diabetic patients with chronic PD had the highest. IgM antibodies were detected in diabetic and non-diabetic with chronic PD. IgG antibodies were detected in patients with T2DM and chronic PD, non-diabetic patients with chronic PD, and healthy individuals. In conclusion, IL-18 was detected in low concentrations in gingival crevicular fluid of patients with T2DM and chronic PD. This could be due to a dysregulation of immune-inflammatory responses secondary to diabetes, or by the presence of IL-18 binding protein in gingival fluid. Low levels of IgG antibodies in T2DM patients with PD could be due to the formation of immune complexes, which would explain the greater periodontal damage these patients present.
Keywords
Antibodies, Porphyromonas gingivalis, Cytokines, Type 2 Diabetes, Periodontitis
To cite this article
Romero-Herrera Coralia, De La Rosa-Ramírez Antonio Manuel, Rosas-Taraco Adrián Geovanni, Limón-Flores Alberto Yairh, Arce-Mendoza Alma Yolanda, IL-18 and Anti- P. gingivalis Antibodies in Patients with Diabetes and Chronic Periodontitis, International Journal of Immunology. Vol. 4, No. 4, 2016, pp. 20-26. doi: 10.11648/j.iji.20160404.11
Copyright
Copyright © 2016 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Saini, R., Marawar, P. P., Shete, S. & Saini, S. Periodontitis, A True Infection. J. Glob. Infect. Dis. 2009 1, 149–150.
[2]
Association, A. D. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2014 37, S81–S90.
[3]
Löe, H. Periodontal Disease: The sixth complication of diabetes mellitus. Diabetes Care 1993 16, 329–334.
[4]
Preshaw, P. M. et al. Periodontitis and diabetes: a two-way relationship. Diabetologia 2011 55, 21–31.
[5]
Herrera Pombo, J. L., Goday Arno, A. & Herrera González, D. Efectos de la diabetes sobre las enfermedades periodontales. Av. En Diabetol. 2013 29, 145–150.
[6]
Nakamura, K., Okamura, H., Wada, M., Nagata, K. & Tamura, T. Endotoxin-induced serum factor that stimulates gamma interferon production. Infect. Immun. 1989 57, 590–595.
[7]
Delaleu, N. & Bickel, M. Interleukin-1 beta and interleukin-18: regulation and activity in local inflammation. Periodontol. 2000 2004 35, 42–52.
[8]
Esposito, K., Marfella, R. & Giugliano, D. Plasma interleukin-18 concentrations are elevated in type 2 diabetes. Diabetes Care 2004 27, 272.
[9]
Orozco, A., Gemmell, E., Bickel, M. & Seymour, G. J. Interleukin 18 and periodontal disease. J. Dent. Res. 2007 86, 586–593.
[10]
Teles, R., Teles, F., Frias-Lopez, J., Paster, B. & Haffajee, A. Lessons learned and unlearned in periodontal microbiology. Periodontol. 2000 2013 62, 95–162.
[11]
Lovegrove, J. M. Dental plaque revisited: bacteria associated with periodontal disease. J. N. Z. Soc. Periodontol. 2004 7–21.
[12]
Mineoka, T. et al. Site-Specific Development of Periodontal Disease Is Associated With Increased Levels of Porphyromonas gingivalis, Treponema denticola, and Tannerella forsythia in Subgingival Plaque. J. Periodontol. 2008 79, 670–676.
[13]
Owen, J., Punt, J. & Stranford, S. Kuby Immunology. (Mc Graw Hill Interamericana Editores, 2014).
[14]
Kalia, K., Sharma, S. & Mistry, K. Non-enzymatic glycosylation of immunoglobulins in diabetic nephropathy. Clin. Chim. Acta Int. J. Clin. Chem. 2004 347, 169–176.
[15]
Mistry, K. & Kalia, K. Non enzymatic glycosylation of IgG and their urinary excretion in patients with diabetic nephropathy. Indian J. Clin. Biochem. IJCB 2009 24, 159–165.
[16]
Kim, M.-R., Yu, S.-A., Kim, M.-Y., Choi, K. M. & Kim, C.-W. Analysis of glycated serum proteins in type 2 diabetes patients with nephropathy. Biotechnol. Bioprocess Eng. 2014 19, 83–92.
[17]
Loe, H. & Silness, J. Periodontal Disease in Pregnancy. Prevalence and Severity. Acta Odontol. Scand. 1963 21, 533–551.
[18]
Turesky, S., Gilmore, N. D. & Glickman, I. Reduced plaque formation by the chloromethyl analogue of victamine C. J. Periodontol. 1970 41, 41–43.
[19]
Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976 72, 248–254.
[20]
Gupta, G. Gingival crevicular fluid as a periodontal diagnostic indicator- I: Host derived enzymes and tissue breakdown products. J. Med. Life 2012 5, 390–397.
[21]
Suchanek, H. et al. High serum interleukin-18 concentrations in patients with coronary artery disease and type 2 diabetes mellitus. Eur. Cytokine Netw. 2005 16, 177–185.
[22]
Moriwaki, Y. et al. Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism. 2003 52, 605–608.
[23]
Aso, Y., Okumura, K.-I., Takebayashi, K., Wakabayashi, S. & Inukai, T. Relationships of plasma interleukin-18 concentrations to hyperhomocysteinemia and carotid intimal-media wall thickness in patients with type 2 diabetes. Diabetes Care 2003 26, 2622–2627.
[24]
Thorand, B. et al. Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the Monica/Kora Augsburg Study, 1984-2002. Diabetes 2005 54, 2932–2938.
[25]
Nair, V., Bandyopadhyay, P., Kundu, D. & Das, S. Estimation of interleukin-18 in the gingival crevicular fluid and serum of Bengali population with periodontal health and disease. J. Indian Soc. Periodontol. 2016 20, 260–264.
[26]
Pradeep, A. r., Daisy, H., Hadge, P., Garg, G. & Thorat, M. Correlation of Gingival Crevicular Fluid Interleukin-18 and Monocyte Chemoattractant Protein-1 Levels in Periodontal Health and Disease. J. Periodontol. 2009 80, 1454–1461.
[27]
Venza, I. et al. Proinflammatory gene expression at chronic periodontitis and peri-implantitis sites in patients with or without type 2 diabetes. J. Periodontol. 2010 81, 99–108.
[28]
Novick, D. et al. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 1999 10, 127–136.
[29]
Foster, N., Andreadou, K., Jamieson, L., Preshaw, P. M. & Taylor, J. J. VIP inhibits P. gingivalis LPS-induced IL-18 and IL-18BPa in monocytes. J. Dent. Res. 2007 86, 883–887.
[30]
Krásná, E. et al. IL-18 receptor expression on epithelial cells is upregulated by TNF alpha. Inflammation 2005 29, 33–37.
[31]
Shetty, N., Thomas, B. & Ramesh, A. Comparison of neutrophil functions in diabetic and healthy subjects with chronic generalized periodontitis. J. Indian Soc. Periodontol. 2008 12, 41–44.
[32]
Robertson, S. E. et al. Expression and alternative processing of IL-18 in human neutrophils. Eur. J. Immunol. 2006 36, 722–731.
[33]
Johnson, R. B. & Serio, F. G. Interleukin-18 concentrations and the pathogenesis of periodontal disease. J. Periodontol. 2005 76, 785–790.
[34]
Tardif, F., Ross, G. & Rouabhia, M. Gingival and dermal fibroblasts produce interleukin-1 beta converting enzyme and interleukin-1 beta but not interleukin-18 even after stimulation with lipopolysaccharide. J. Cell. Physiol. 2004 198, 125–132.
[35]
Yuan, K. et al. Detection of putative periodontal pathogens in non-insulin-dependent diabetes mellitus and non-diabetes mellitus by polymerase chain reaction. J. Periodontal Res. 2001 36, 18–24.
[36]
Field, C. A., Gidley, M. D., Preshaw, P. M. & Jakubovics, N. Investigation and quantification of key periodontal pathogens in patients with type 2 diabetes. J. Periodontal Res. 2012 47, 470–478.
[37]
Ojima, M. et al. Relationship of Periodontal Bacterium Genotypic Variations With Periodontitis in Type 2 Diabetic Patients. Diabetes Care 2005 28, 433–434.
[38]
Onoue, S. et al. Serum antibodies of periodontitis patients compared to the lipopolysaccharides of Porphyromonas gingivalis and Fusobacterium nucleatum. Microbiol. Immunol. 2003 47, 51–55.
[39]
Kajiya, M. et al. Role of periodontal pathogenic bacteria in RANKL-mediated bone destruction in periodontal disease. J. Oral Microbiol. 2010 2.
[40]
Kuramoto, A. et al. The formation of immune complexes is involved in the acute phase of periodontal destruction in rats. J. Periodontal Res. 2012 47, 455–462.
Browse journals by subject